These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22998497)

  • 1. Down-modulation of expression, or dephosphorylation, of IG20/MADD in tumor necrosis factor-related apoptosis-inducing ligand-resistant thyroid cancer cells makes them susceptible to treatment with this ligand.
    Li LC; Jayarama S; Pilli T; Qian L; Pacini F; Prabhakar BS
    Thyroid; 2013 Jan; 23(1):70-8. PubMed ID: 22998497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer.
    Saini S; Sripada L; Tulla K; Qiao G; Kunda N; Maker AV; Prabhakar BS
    Endocr Relat Cancer; 2019 Jun; 26(6):551-563. PubMed ID: 30999276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis.
    Subramanian M; Pilli T; Bhattacharya P; Pacini F; Nikiforov YE; Kanteti PV; Prabhakar BS
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1467-71. PubMed ID: 19190106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Akt-phosphorylated mitogen-activated kinase-activating death domain protein (MADD) inhibits TRAIL-induced apoptosis by blocking Fas-associated death domain (FADD) association with death receptor 4.
    Li P; Jayarama S; Ganesh L; Mordi D; Carr R; Kanteti P; Hay N; Prabhakar BS
    J Biol Chem; 2010 Jul; 285(29):22713-22. PubMed ID: 20484047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.
    Turner A; Li LC; Pilli T; Qian L; Wiley EL; Setty S; Christov K; Ganesh L; Maker AV; Li P; Kanteti P; Das Gupta TK; Prabhakar BS
    PLoS One; 2013; 8(2):e56817. PubMed ID: 23457619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MADD is a downstream target of PTEN in triggering apoptosis.
    Jayarama S; Li LC; Ganesh L; Mardi D; Kanteti P; Hay N; Li P; Prabhakar BS
    J Cell Biochem; 2014 Feb; 115(2):261-70. PubMed ID: 24038283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation. Knockdown enhances TRAIL-induced apoptosis of cancer cells.
    Mulherkar N; Prasad KV; Prabhakar BS
    J Biol Chem; 2007 Apr; 282(16):11715-21. PubMed ID: 17314102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MADD, a splice variant of IG20, is indispensable for MAPK activation and protection against apoptosis upon tumor necrosis factor-alpha treatment.
    Kurada BRVVSN; Li LC; Mulherkar N; Subramanian M; Prasad KV; Prabhakar BS
    J Biol Chem; 2009 May; 284(20):13533-13541. PubMed ID: 19289468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC.
    Ramaswamy M; Efimova EV; Martinez O; Mulherkar NU; Singh SP; Prabhakar BS
    Oncogene; 2004 Aug; 23(36):6083-94. PubMed ID: 15208670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAIL suppresses human breast cancer cell migration via MADD/CXCR7.
    Wang R; Li JC
    Asian Pac J Cancer Prev; 2015; 16(7):2751-6. PubMed ID: 25854358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.
    Thakkar H; Chen X; Tyan F; Gim S; Robinson H; Lee C; Pandey SK; Nwokorie C; Onwudiwe N; Srivastava RK
    J Biol Chem; 2001 Oct; 276(42):38361-9. PubMed ID: 11461904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MADD/DENN splice variant of the IG20 gene is necessary and sufficient for cancer cell survival.
    Mulherkar N; Ramaswamy M; Mordi DC; Prabhakar BS
    Oncogene; 2006 Oct; 25(47):6252-61. PubMed ID: 16682944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells.
    Li LC; Jayaram S; Ganesh L; Qian L; Rotmensch J; Maker AV; Prabhakar BS
    Am J Obstet Gynecol; 2011 Oct; 205(4):362.e12-25. PubMed ID: 21855847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneously targeting Bcl-2 and Akt pathways reverses resistance of nasopharyngeal carcinoma to TRAIL synergistically.
    Li SS; Tang QL; Wang SH; Chen YH; Liu JJ; Yang XM
    Tumori; 2011; 97(6):762-70. PubMed ID: 22322844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways.
    Gunda V; Bucur O; Varnau J; Vanden Borre P; Bernasconi MJ; Khosravi-Far R; Parangi S
    Cell Death Dis; 2014 Mar; 5(3):e1104. PubMed ID: 24603332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
    Chen KF; Yeh PY; Hsu C; Hsu CH; Lu YS; Hsieh HP; Chen PJ; Cheng AL
    J Biol Chem; 2009 Apr; 284(17):11121-33. PubMed ID: 19261616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IG20, a MADD splice variant, increases cell susceptibility to gamma-irradiation and induces soluble mediators that suppress tumor cell growth.
    Efimova E; Martinez O; Lokshin A; Arima T; Prabhakar BS
    Cancer Res; 2003 Dec; 63(24):8768-76. PubMed ID: 14695193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of IG20 splice variants in TRAIL resistance.
    Prabhakar BS; Mulherkar N; Prasad KV
    Clin Cancer Res; 2008 Jan; 14(2):347-51. PubMed ID: 18223207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers.
    Nam SY; Jung GA; Hur GC; Chung HY; Kim WH; Seol DW; Lee BL
    Cancer Sci; 2003 Dec; 94(12):1066-73. PubMed ID: 14662022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs.
    Efimova EV; Al-Zoubi AM; Martinez O; Kaithamana S; Lu S; Arima T; Prabhakar BS
    Oncogene; 2004 Feb; 23(5):1076-87. PubMed ID: 14716293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.